Control of aggressive fibromatosis by treatment with imatinib mesylate: a step forward?
J Cancer Res Clin Oncol
; 135(2): 325-6, 2009 Feb.
Article
em En
| MEDLINE
| ID: mdl-18825412
ABSTRACT
Numerous studies referring to conventional chemotherapy for aggressive fibromatosis with the use of doxorubicin, cyclophosphamide, vincristin, vinblastine and other drugs have been published. Imatinib mesylate is a recently developed oral anticancer agent designed to selectively inhibit tyrosine kinases implicated in oncogenesis and it seems to represent a promising opportunity (also in first line) in the treatment of patients with advanced disease not candidate to prior surgery.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Fibromatose Agressiva
/
Antineoplásicos
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
J Cancer Res Clin Oncol
Ano de publicação:
2009
Tipo de documento:
Article